Literature DB >> 29760505

Low-value approvals and high prices might incentivize ineffective drug development.

Vinay Prasad1,2,3, Christopher McCabe4, Sham Mailankody5.   

Abstract

Mesh：

Year:  2018        PMID： 29760505     DOI： 10.1038/s41571-018-0030-2

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

Authors:  Taylor Bucy; John M Zoscak; Motomi Mori; Uma Borate
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  The value of anticancer drugs - a regulatory view.

Authors:  Francesco Pignatti; Ulla Wilking; Douwe Postmus; Nils Wilking; Julio Delgado; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2021-12-06       Impact factor: 66.675

Review 3.  Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.

Authors:  Alfredo Addeo; Glen J Weiss; Bishal Gyawali
Journal:  JAMA Netw Open       Date:  2019-05-03

4.  ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.

Authors:  Freddy E Escorcia; Jacob L Houghton; Dalya Abdel-Atti; Patricia R Pereira; Andrew Cho; Nicholas T Gutsche; Kwamena E Baidoo; Jason S Lewis
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 5.  Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

Authors:  Vincent Lemaire; Colby S Shemesh; Anand Rotte
Journal:  J Exp Clin Cancer Res       Date:  2021-10-01

6.  Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.

Authors:  Kiu Tay-Teo; André Ilbawi; Suzanne R Hill
Journal:  JAMA Netw Open       Date:  2019-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.